First year at the LégiaPark
On March 12th, Amyl Therapeutics celebrated its first year at the LégiaPark. Since the move, Amyl has grown to 9 team members, and welcomed Chiara, Damien, Sophia, Sandra and Dafni. Our team is growing, and our projects are evolving, primarily in the field of Alzheimer’s disease. We are dedicated to find an efficacious and safe […]
Bio-Neuroscience
Amyl Therapeutics had joined Bio-Neuroscience, a premier partnership and investment summit for the world’s leaders in drug discovery and development in the field of central nervous system (CNS) neuroscience. It took place from February 25 to 27, 2025 in Amsterdam. A great opportunity to connect with key people in neuroscience. We are eager to take […]
The Amyl Team – Who does what ?
Pierre Vandepapelière – CEO “As the CEO of Amyl Therapeutics, my role is to lead with vision, passion, and purpose. In a field as challenging as neurodegeneration, every decision brings us closer to potential breakthroughs that could one day impact the lives of patients, families, and communities. I’m proud to lead a team that’s committed […]
Bio-Europe Fall in Stockholm
We are excited to announce that Pierre Vandepapeliere, our CEO and Damien Toulorge, our Chief Scientific Officer, will be attending BioEurope 2024. This premier event brings together leaders in the biopharmaceutical industry to discuss innovation, partnership opportunities, and the future of biotech. We look forward to engaging with fellow professionals, sharing insights, and exploring collaborations […]
Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis
LIEGE, Belgium – June 3, 2021: Amyl Therapeutics (‘Amyl’), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq – a […]